Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers

This study has been completed.
Information provided by (Responsible Party):
Alcon Research Identifier:
First received: May 2, 2007
Last updated: May 23, 2012
Last verified: May 2012
Compare the effect of Xalatan with benzalkonium chloride on the ocular surface to those effects observed with Travatan Z without benzalkonium chloride after a single dose

Condition Intervention Phase
Drug: Travatan® Z
Drug: Xalatan®
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Tear Break Up Time [ Time Frame: Day ]

Secondary Outcome Measures:
  • Safety [ Time Frame: Onset ]

Estimated Enrollment: 30
Study Start Date: May 2007
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Adults with primary open-angle glaucoma, ocular hypertension or pigment dispersion glaucoma

Exclusion Criteria:

  • Age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00468988

United States, Florida
Orlando, Florida, United States, 32801
Sponsors and Collaborators
Alcon Research
Study Director: Mark Jasek, PhD Alcon Research
  More Information

Responsible Party: Alcon Research Identifier: NCT00468988     History of Changes
Other Study ID Numbers: SMA-06-21 
Study First Received: May 2, 2007
Last Updated: May 23, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Benzalkonium Compounds
Antihypertensive Agents
Anti-Infective Agents, Local
Anti-Infective Agents processed this record on September 29, 2016